FOR IMMEDIATE RELEASE
Contact: Andrew Lavin
A. Lavin Communications
ANTI-INFLAMMATORY DRUGS (COXIBS) INTERFERE WITH ASPIRIN’S CLOTTING ABILITY
ACCORDING TO BEN-GURION UNIVERSITY OF THE NEGEV STUDY
BEER-SHEVA, ISRAEL -- December 23, 2009 -- A new study conducted at Ben-Gurion University of the Negev (BGU) reveals that Celebrex and other anti-inflammatory coxib medications may counter the positive effects of aspirin in preventing blood clots. The research, published in the ), indicates that people who are taking aspirin and coxibs together are in fact inhibiting the aspirin’s effectiveness in preventing heart attacks and strokes. “This finding strongly suggests that humans who are consuming coxibs and a low dose of aspirin simultaneously are exposed to a greater risk of cardiovascular events,” said Professor Gilad Rimon, Department of Clinical Pharmacology, Ben-Gurion University of the Negev in Israel. In the past decade, a new group of anti-inflammatory drugs, coxibs, which include Celebrex and Arcoxia was developed to treat arthritis as well as other pain. Arthritis patients who take Celebrex are instructed to take low-dose aspirin to counteract Celebrex’s own potential clot-promoting effect. Aspirin is the oldest and one of the most effective non steroidal anti-inflammatory drugs. It is also well known for its ability to prevent the blood clots that can potentially lead to heart attack and stroke. Therefore, doctors often advise patients who are more prone to heart-related illnesses to take a daily tablet of low dose aspirin (81 mg). Approximately, 50 million Americans take aspirin every day to reduce their risk of cardiovascular diseases. Now, the BGU research suggests that in the presence of coxibs, asprin’s protective role in preventing new blood clots is blunted. This finding mirrors a cooperative study conducted at the University of Michigan, Ann Arbor that showed for the first time that Celebrex and other coxibs directly interfere with the protective qualities of aspirin.
Gilad Rimon a,b,1,Ranjinder S. Sidhua,1, D. Adam Lauverc,1, Jullia Y. Leea, Narayan P.
Sharmaa,Chong Yuana, Ryan A. Frielera, Raymond C. Trievela, Benedict R. Lucchesic and
William L. Smitha,2
a Department of Biological Chemistry, University of Michigan, Ann Arbor, MI 48109;
b Department of Clinical Pharmacology, Ben-Gurion University of the Negev, P.O. Box 653, Beer-
Sheva 84105, Israel; and
c Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109 About American Associates, Ben-Gurion University of the Negev
American Associates, Ben-Gurion University of the Negev plays a vital role in sustaining David
Ben-Gurion's vision, creating a world-class institution of education and research in the Israeli
desert, nurturing the Negev community and sharing the University's expertise locally and around
the globe. With some 19,000 students on campuses in Beer-Sheva, Sede Boqer and Eilat in Israel’s
southern desert, BGU is a university with a conscience, where the highest academic standards are
integrated with community involvement, committed to sustainable development of the Negev. For
more information, please visit www.aabgu.org.
Michael T. Coyle EXPERIENCE SUMMARY Thirty-three years as a United States Naval Officer, achieving the rank of Rear Admiral. Extensive experience in operations, engineering and maintenance of nuclear and conventional power systems. Eleven years as a senior manager and executive in the commercial nuclear power field and two and a half years as a Department of Energy (DOE) contractor.
SEZIONE SCIENTIFICA - Revisione Cochrane per il medico di famiglia Questa rubrica presenta i risultati di PREVENZIONE DELLA una revisione sistematica pubblicata MALARIA NEI dalla Cochrane Collaboration nella VIAGGIATORI: QUALE Cochrane Library (www.cochrane.org). Volutamente limitato a un campo di ANTIMALARICO? ricerca circoscritto, quest’articolo ri-specchia lo stato